Business Context and Reporting Period
Company: China Pharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2024
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) for an at-the-market equity offering.
Key Financial Metrics
This filing does not report historical financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the proposed capital raise:
- Maximum Offering Size: Up to $600,000 aggregate offering price.
- Security Type: Common Stock (par value $0.001 per share).
- Minimum Price Floor: $0.15 per share.
- Expected Proceeds: Indeterminate at this time; dependent on the number of shares sold and market prices.
Material Changes and Agreement Terms
On December 12, 2024, the Company entered into a Securities Purchase Agreement (SPA) with an institutional investor. Key terms include:
- Commitment Period: December 12, 2024, to December 31, 2024.
- Pricing Mechanism: At-the-market price, defined as the lower of the prior day's closing price or the five-day average closing price, subject to the $0.15 floor.
- Repricing Rights: The Investor may adjust the purchase price downward if delivery is delayed past 1:00 pm E.T. and the market price has dropped.
- Return Rights: The Investor may return any or all shares within one business day of receipt if market conditions are deemed unfavorable.
- Most Favored Nation (MFN) Treatment: If the Company enters into a more favorable financing agreement within 30 days, the new terms apply retroactively. The value difference will be issued as a convertible note.
Outlook, Risks, and Contingencies
Outlook: The offering is designed to raise capital with no minimum closing requirement. The actual proceeds are not determinable until shares are sold.
Risks and Contingencies:
- Dilution: Issuance of new shares will dilute existing shareholders.
- Market Volatility: The Investor's right to return shares or reprice downward introduces uncertainty regarding final proceeds.
- MFN Adjustments: Future financing could trigger retroactive adjustments, potentially resulting in the issuance of convertible notes to the Investor.
- Termination: The offering terminates on the earlier of the $600,000 cap being reached, the Registration Statement becoming ineffective, or December 31, 2024.
Investor Verification Checklist
- Verify the current trading price of CPHI on NYSE American to assess the likelihood of sales occurring above the $0.15 floor.
- Review the full text of the Securities Purchase Agreement (Exhibit 1.1) for specific repricing formulas and MFN adjustment mechanics.
- Monitor subsequent filings to determine if the $600,000 cap was reached or if the offering was terminated early.
- Check for any new financing announcements within 30 days of December 12, 2024, which could trigger MFN adjustments.